ARTICLE | Management Tracks
Plus: Edward Dulac to become CFO at Intellia, and updates from Altimmune, Bayer, Compass, Sensorion and Neurona
By Gunjan Ohri, Data Content Analyst
June 28, 2024 1:03 AM UTC
In a bid to grow its U.S. footprint, Forbion hired Josh Brumm as general partner and unveiled plans for a new office in the U.S. in Boston. Brumm, who will be located at the European VC’s new Boston address, was most recently president and CEO of muscle disease company Dyne Therapeutics Inc. (NASDAQ:DYN), a Forbion portfolio company. Forbion said Brumm will hunt for new opportunities in North America and Europe and support existing portfolio companies, including those “working towards U.S. expansion.”
Edward Dulac will become EVP, CFO at Intellia Therapeutics Inc. (NASDAQ:NTLA) on July 22, succeeding Glenn Goddard, who is stepping down June 30. Dulac was CFO at Fate Therapeutics Inc. (NASDAQ:FATE), before which he held several roles at Celgene Corp. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652833/forbion-taps-dyne-vet-brumm-to-guide-growing-u-s-presence